查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128958

緩解疾病藥物市場：依藥物類別、適應症、治療方法、給藥途徑、通路、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026-2033年預測

Disease-Modifying Agents Market, By Drug Class, By Indication, By Therapy Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 254 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，緩解疾病藥物市場價值將達到 61.051 億美元，並將在 2026 年至 2033 年期間以 6.6% 的複合年成長率成長。

緩解疾病藥物是一類處方藥，它不僅能治療症狀，還能改變疾病的潛在機制，例如自體免疫反應和發炎過程，進而抑制疾病的進展。市場包括多種傳統緩解疾病藥物（TDMA），例如胺基甲基葉酸、柳氮磺吡啶、羥氯喹、羥氯奎、黴酚酸、干擾素BETA和glatiramer acetate。

目標疾病包括類風濕性關節炎、多發性硬化症（MS）、紅斑性狼瘡和其他自體免疫疾病。根據國際多發性硬化症聯盟（MS International Federation）預測，到2025年，全球將有約290萬人罹患多發性硬化症（MS）。目前市場主要由成熟的學名藥主導，但也需要差異化的注射療法。此外，治療方案的選擇取決於疾病的嚴重程度、安全性、監測需求以及治療順序。因此，每種藥物的效用取決於其適應症和作用機制。

緩解疾病藥物市場－市場動態

擴大符合慢性自體免疫疾病治療條件的患者人數

自體免疫疾病和發炎性疾病患者群體的整體擴大，使得現有疾病修正治療的目標人口人群更加廣泛。例如，美國疾病管制與預防中心（CDC）2025年的一項分析預測，屆時美國將有6,710萬成年人被診斷出患有關節炎，其中1,060萬人將患有類風濕性關節炎。此外，國際多發性硬化症協會（MSIF）報告稱，全球有290萬人患有多發性硬化症。因此，這些疾病盛行率的上升推動了此類藥物的使用，而這些藥物通常針對需要長期治療的慢性疾病。因此，持續的治療需求影響治療的啟動率、後續觀察、治療方案的調整以及患者的用藥依從性。由此可見，疾病本身的存在促使人們繼續使用這些藥物。此外，藥物類別的選擇取決於既定的治療方案、安全性、給藥的便利性以及疾病控制的現狀。

緩解疾病藥物市場－市場區隔分析：

全球緩解疾病藥物市場按藥物類別、適應症、治療類型、給藥途徑、分銷管道和地區進行細分。

按藥物類別分類，傳統的合成緩解疾病抗風濕藥物（DMARDs），例如胺基甲基葉酸、來氟米特、羥氯喹和柳氮磺吡啶，由於其長期應用已得到廣泛認可，在類風濕性關節炎和其他炎症性疾病的治療中佔據了很大的市場佔有率。胺基甲基葉酸仍是許多中度至重度類類風濕性關節炎患者的第一線DMARD。生物製藥和標靶合成藥物是DMARDs領域中快速發展的類別。這主要是因為它們能夠針對TNF/JAK通路，從而改善疾病控制，並在常規療法無效時被廣泛接受為二線治療方案。根據世界衛生組織（WHO）估計，全球約有1800萬人患有類類風濕性關節炎。

緩解疾病藥物市場－區域分析

北美地區憑藉其完善的專業醫療保健基礎設施、成熟的保險報銷體係以及自體免疫疾病的高發病率，仍然是至關重要的戰略要地，這使得緩解疾病藥物的持續使用成為可能。根據美國疾病管制與預防中心 (CDC) 2025 年的預測，美國有 6,710 萬名成年人被診斷出患有關節炎，其中 1,060 萬人患有類風濕性關節炎。因此，傳統 DMARDs 的目標患者群體規模相當龐大。多發性硬化症的出現，為該藥物的治療增添了新的特殊適應症，需要長期治療和監測。此外，監管政策的發展將影響產品的可及性和替代療法的使用。美國食品藥物管理局 (FDA) 已於 2025 年批准了Siponimod和Cladribine的學名藥用於治療多發性硬化症。因此，北美地區存在著龐大的臨床需求，同時其完善的法規環境也有利於推廣實證、便利的治療方案。

歐洲擁有完善的風濕病和神經病醫療保健體系、系統性的藥物評估以及對慢性免疫介導疾病的持續管理，因此是一個重要的市場。根據英國多發性硬化症協會統計，英國有超過15萬名多發性硬化症患者，每年新增病例超過7,100例，顯示神經系統疾病治療的需求持續存在。監管趨勢也顯示產品更新換代將持續進行。 2025年，歐洲藥品管理局（EMA）批准了Riulvy上市，Riulvy是替戈米富馬酸酯的學名藥，用於治療復發型多發性硬化症。此類批准擴大了產品選擇範圍，但也可能增加現有產品的替代壓力。傳統的DMARDs（緩解疾病抗風濕藥），例如胺基甲基葉酸、羥氯喹、柳氮磺吡啶和來氟米特，仍然是基於指南的風濕病臨床實踐中常用的藥物。

目錄

第1章：緩解疾病藥物市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：緩解疾病的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：緩解疾病藥物產業的分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：緩解疾病藥物市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：緩解疾病藥物的市場趨勢

  • 2025年緩解疾病藥物市佔率分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章緩解疾病藥物市場：依藥物類別分類

  • 概述
    • 基於細分市場的市場佔有率分析：按藥物類別分類
    • 傳統合成緩解疾病
    • 生物緩解疾病
    • 標靶合成藥物
    • 干擾素
    • 單株抗體
    • 免疫調節藥物
    • 其他

第8章緩解疾病藥物市場：依適應症分類

  • 概述
    • 基於細分市場的市佔率分析：按適應症
    • 多發性硬化症
    • 類風濕性關節炎
    • 乾癬性關節炎
    • 僵直性脊椎炎/中軸型脊椎關節炎
    • 全身性紅斑性狼瘡
    • 系統性硬皮症
    • 其他

第9章緩解疾病藥物市場：依治療類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按治療類型
    • 聯合治療
    • 單藥治療
    • 其他

第10章：緩解疾病藥物市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 口服
    • 皮下
    • 肌肉內部
    • 靜脈注射/輸液
    • 其他

第11章緩解疾病藥物市場：依通路分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分銷管道分類
    • 網路藥房
    • 醫院藥房
    • 零售藥房
    • 其他

第12章緩解疾病藥物市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第13章：主要供應商分析：緩解疾病藥物產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Biogen Inc.
    • Merck KGaA
    • Sanofi
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • AbbVie Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Eli Lilly and Company
    • Bristol Myers Squibb
    • UCB SA
    • Bayer AG
    • Viatris Inc.
    • Fresenius Kabi
    • Accord Healthcare
    • Others

第14章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7346

Disease-Modifying Agents Market size was valued at US$ 6,105.1 Million in 2025, expanding at a CAGR of 6.6% from 2026 to 2033.

Disease-modifying agents are a class of prescription drugs that modify the underlying disease mechanisms, such as the autoimmune response or inflammatory process, and reduce their progression, as opposed to only treating the symptoms. The market offers a range of traditional disease-modifying agents (TDMAs), including methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, mycophenolate, interferon beta, and glatiramer acetate.

Disease areas comprise rheumatoid arthritis, multiple sclerosis, lupus, and other autoimmune diseases. According to the MS International Federation, as of 2025, there are approximately 2.9 million people worldwide living with multiple sclerosis (MS). The overall market is dominated by established generic drugs, but there is also a need for differentiated injectable therapies. Additionally, the choice of therapy depends on the severity of the condition, safety, the need for monitoring, and the sequence of treatment options; therefore, the relevance of each drug depends on its indication and mechanism of action.

Disease-Modifying Agents Market- Market Dynamics

Expanding Chronic Autoimmune Disease Treatment Pool

The overall expanding treated population within autoimmune/inflammatory diseases contributes to the addressable base for existing disease-modifying therapies. In particular, according to the 2025 CDC analysis, there are 67.1 million U.S. adults with diagnosed arthritis, including 10.6 million individuals with rheumatoid arthritis. The Multiple Sclerosis International Federation reported that 2.9 million people worldwide are living with multiple sclerosis. As a result, disease prevalence boosts the therapies' utilization as they usually address a chronic condition, which involves long-term treatment courses. Consequently, the continuous need for treatment affects the rate of initiation, monitoring, switches, and adherence. Thus, the presence of diseases contributes to the continuous utilization of drugs. Additionally, the class preference is dependent on the established treatment regimen, safety, convenience of administration, and disease control.

Disease-Modifying Agents Market- Segmentation Analysis:

The Global Disease-Modifying Agents Market is segmented on the basis of Drug Class, Indication, Therapy Type, Route of Administration, Distribution Channel, and Region.

By drug class, Conventional synthetic disease modifying agents (DMARDs) have a large proportion of total revenues due to the well-established and long term usage of methotrexate, leflunomide, hydroxychloroquine and sulfasalazine; especially in rheumatoid and other inflammatory diseases. Methotrexate remains the first line of choice DMARD for many patients who have moderate to severe levels of rheumatoid arthritis. Biologic and targeted synthetic agents are rapidly developing categories of DMARDs. This is primarily being driven by the ability to target TNF/JAK pathways which results in better control of disease and increased acceptance of these agents as second-line treatments when conventional therapies fail to provide an adequate response. It has been estimated by the World Health Organization (WHO) that there are approximately 18 million individuals living with rheumatoid arthritis across the globe.

Disease-Modifying Agents Market- Geographical Insights

North America remains an important strategic location due to specialist infrastructure development, established mechanisms for reimbursements, and the prevalence of autoimmune diseases enabling sustained use of disease-modifying products. According to CDC estimates for 2025, there are 67.1 million adult patients in the United States with diagnosed arthritis, 10.6 million of whom suffer from rheumatoid arthritis. Thus, there is a sufficiently large target patient population for conventional DMARDs. The addition of multiple sclerosis provides another specialized indication requiring prolonged treatment and monitoring. Moreover, regulatory activity impacts product access and substitution: the FDA has approved generic versions of siponimod and cladribine in 2025 for the treatment of multiple sclerosis. Thus, North America has sufficient clinical need combined with a well-established regulatory environment that incentivizes evidence-based, convenient treatment options.

Europe presents a significant market due to the established systems of rheumatology and neurology care, structured medical product assessments, and sustained management of chronic immune-mediated diseases. According to the UK MS Society, there are more than 150,000 people living with multiple sclerosis in the country and more than 7,100 new cases diagnosed each year demonstrating the consistent need for neurological treatments. The regulatory activity also shows continuous product turnover, in 2025, the EMA approved marketing authorization for Riulvy a generic tegomil fumarate intended for treating relapsing remitting multiple sclerosis. Approvals like these may expand product choice while increasing the pressure on the substitution of existing products. Conventional DMARDs remain integrated into guideline-based rheumatology practice-methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide.

Disease-Modifying Agents Market- Competitive Landscape:

Competition is distributed among diversified pharmaceutical companies, specialty immunology developers, and manufacturers supplying established or generic disease-modifying therapies. Differentiation increasingly depends on mechanism, administration frequency, safety profile, clinical evidence, and lifecycle expansion rather than product novelty alone. Novartis illustrates this transition through Kesimpta, its B-cell-directed therapy for relapsing multiple sclerosis. In September 2025, company reported ARTIOS and ALITHIOS findings indicated that more than 90% of relevant participants achieved no evidence of disease activity or remained progression-free under specified treatment settings. Biogen simultaneously maintained an established MS portfolio including Avonex and Plegridy, preserving the relevance of interferon-based therapies. Overall, competitive strength increasingly rests on evidence depth, convenience, and differentiated clinical positioning.

Recent Developments:

In September 2025, Novartis announced new data regarding ARTIOS and ALITHIOS studies on Kesimpta in relapsing multiple sclerosis. Over 90% of patients reached particular disease control objectives, reinforcing the rationale for the use of the drug both initially and after switching.

In July 2025, the European Medicines Agency (EMA)/Neuraxpharm granted marketing authorization to Riulvy, a generic tegomil fumarate, for relapsing-remitting multiple sclerosis. This approval increases the list of European products available for MS treatments.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DISEASE-MODIFYING AGENTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biogen Inc.
  • Merck KGaA
  • Sanofi
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Eli Lilly and Company
  • Bristol Myers Squibb
  • UCB S.A.
  • Bayer AG
  • Viatris Inc.
  • Fresenius Kabi
  • Accord Healthcare
  • Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033

  • Conventional Synthetic Disease-Modifying Agents
  • Biologic Disease-Modifying Agents
  • Targeted Synthetic Agents
  • Interferons
  • Monoclonal Antibodies
  • Immunomodulators
  • Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033

  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis / Axial Spondyloarthritis
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
  • Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2020 - 2033

  • Combination therapy
  • Monotherapy
  • Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Oral
  • Subcutaneous
  • Intramuscular
  • Intravenous / Infusion
  • Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Disease-Modifying Agents Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Disease-Modifying Agents Market Snippet by Drug Class
    • 2.1.2. Disease-Modifying Agents Market Snippet by Indication
    • 2.1.3. Disease-Modifying Agents Market Snippet by Therapy Type
    • 2.1.4. Disease-Modifying Agents Market Snippet by Route of Administration
    • 2.1.5. Disease-Modifying Agents Market Snippet by Distribution Channel
    • 2.1.6. Disease-Modifying Agents Market Snippet by Country
    • 2.1.7. Disease-Modifying Agents Market Snippet by Region
  • 2.2. Competitive Insights

3. Disease-Modifying Agents Key Market Trends

  • 3.1. Disease-Modifying Agents Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Disease-Modifying Agents Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Disease-Modifying Agents Market Opportunities
  • 3.4. Disease-Modifying Agents Market Future Trends

4. Disease-Modifying Agents Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Disease-Modifying Agents Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Disease-Modifying Agents Market Landscape

  • 6.1. Disease-Modifying Agents Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Disease-Modifying Agents Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
    • 7.1.2. Conventional Synthetic Disease-Modifying Agents
    • 7.1.3. Biologic Disease-Modifying Agents
    • 7.1.4. Targeted Synthetic Agents
    • 7.1.5. Interferons
    • 7.1.6. Monoclonal Antibodies
    • 7.1.7. Immunomodulators
    • 7.1.8. Others

8. Disease-Modifying Agents Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
    • 8.1.2. Multiple Sclerosis
    • 8.1.3. Rheumatoid Arthritis
    • 8.1.4. Psoriatic Arthritis
    • 8.1.5. Ankylosing Spondylitis / Axial Spondyloarthritis
    • 8.1.6. Systemic Lupus Erythematosus
    • 8.1.7. Systemic Sclerosis
    • 8.1.8. Others

9. Disease-Modifying Agents Market - By Therapy Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapy Type, 2025 & 2033 (%)
    • 9.1.2. Combination therapy
    • 9.1.3. Monotherapy
    • 9.1.4. Others

10. Disease-Modifying Agents Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 10.1.2. Oral
    • 10.1.3. Subcutaneous
    • 10.1.4. Intramuscular
    • 10.1.5. Intravenous / Infusion
    • 10.1.6. Others

11. Disease-Modifying Agents Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
    • 11.1.2. Online Pharmacies
    • 11.1.3. Hospital Pharmacies
    • 11.1.4. Retail Pharmacies
    • 11.1.5. Others

12. Disease-Modifying Agents Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Disease-Modifying Agents Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Disease-Modifying Agents Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.18. Denmark
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.18.3. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.18.4. Denmark Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.18.5. Denmark Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.18.6. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.18.7. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.19. Rest of Europe
      • 12.3.19.1. Overview
      • 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.19.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.19.4. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.19.5. Rest of the Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.3.19.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.19.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Disease-Modifying Agents Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.17. Taiwan
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.17.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.17.4. Taiwan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.17.5. Taiwan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.17.6. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.17.7. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.18. Vietnam
      • 12.4.18.1. Overview
      • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.18.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.18.4. Vietnam Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.18.5. Vietnam Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.18.6. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.18.7. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.19. Rest of APAC
      • 12.4.19.1. Overview
      • 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.19.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.19.4. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.19.5. Rest of APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.4.19.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.19.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Disease-Modifying Agents Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Disease-Modifying Agents Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.15. Iran
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.15.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.15.4. Iran Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.15.5. Iran Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.15.6. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.15.7. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.16. Qatar
      • 12.6.16.1. Overview
      • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.16.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.16.4. Qatar Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.16.5. Qatar Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.16.6. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.16.7. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.17. Rest of MEA
      • 12.6.17.1. Overview
      • 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.17.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.17.4. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.17.5. Rest of MEA Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
      • 12.6.17.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.17.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Disease-Modifying Agents Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Biogen Inc.
    • 13.2.2. Merck KGaA
    • 13.2.3. Sanofi
    • 13.2.4. Pfizer Inc.
    • 13.2.5. Teva Pharmaceutical Industries Ltd.
    • 13.2.6. Novartis AG
    • 13.2.7. F. Hoffmann-La Roche Ltd.
    • 13.2.8. AbbVie Inc.
    • 13.2.9. Johnson & Johnson
    • 13.2.10. Amgen Inc.
    • 13.2.11. Eli Lilly and Company
    • 13.2.12. Bristol Myers Squibb
    • 13.2.13. UCB S.A.
    • 13.2.14. Bayer AG
    • 13.2.15. Viatris Inc.
    • 13.2.16. Fresenius Kabi
    • 13.2.17. Accord Healthcare
    • 13.2.18. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us